Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quest Pharmatech Inc V.QPT

Alternate Symbol(s):  QPTFF

Healthcare Biotechnology
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.


TSXV:QPT - Post by User

Quest Pharmatech Inc > Hmm...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(95)
•••
Comment by G1945Von Jul 21, 2022 1:38pm
121 Views
Post# 34840977

RE:Hmm...

RE:Hmm...
ARIMA11 wrote: https://ceo.ca/qpt?628915064c02  
https://pulsenews.co.kr/view.php?sc=30800028&year=2022&no=360177

Canariabio is issuing convertible bonds worth 70 billion won to finance the deal, along with 20 billion won pooled from its affiliated entities.

As pointed out by Zippo on CEO.ca, Canaribio continues to acquire companies. This time in the feed business. The way they make that acquisition is also through a convertable bonds. 90B this time.

In comparison the QPT deal is small potatoes but reading this is not comforting. 


Thanks ARIMA11,  for the explanation.

I did email Pierre Vermette. Have not heard back as yet. 

G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities